BlackRock Health Sciences Trust Stock: price and directors' dealings · United States · SEC (Form 4)

About BlackRock Health Sciences Trust

BlackRock Health Sciences Trust (NYSE: BME, United States) is a listed closed-end fund focused on the health sciences universe. Its investment objective is to deliver total return and income, primarily through long-term capital appreciation. Under normal market conditions, the trust invests at least 80% of assets in equity securities of companies engaged in health sciences and related industries, as well as in equity derivatives with exposure to the sector. For investors seeking a professional-sector healthcare allocation, BME offers a concentrated, actively managed vehicle rather than a broad-market fund. The fund was launched on March 31, 2005 and is part of BlackRock’s closed-end fund platform. BlackRock is headquartered in Wilmington, Delaware, in the United States, while BME itself trades on the NYSE. That structure matters for investors: the trust combines public-market liquidity with an actively managed healthcare portfolio and a distribution policy designed to support income. As of early May 2026, BlackRock reported an annualized distribution rate of roughly 8.01% for BME, underscoring its income-oriented profile. As with all closed-end funds, however, this should not be interpreted as a guaranteed yield. From a competitive standpoint, BME sits in a crowded but specialized corner of the market. It competes with other healthcare closed-end funds, sector mutual funds, and healthcare ETFs. Its main differentiators are BlackRock’s scale, sector research depth, and active security selection. The latest publicly disclosed portfolio snapshot shows a large weighting in established leaders such as Johnson & Johnson, Eli Lilly, Merck, AbbVie, Gilead Sciences, Amgen, UnitedHealth Group, Pfizer, Vertex Pharmaceuticals, and Intuitive Surgical. This mix provides exposure across pharmaceuticals, biotechnology, medical devices, and healthcare services, which helps diversify idiosyncratic risk within the sector. Management continuity is another key point. The trust is led by Erin Xie, PhD, head of BlackRock’s Fundamental Equities Health Sciences team, with Xiang Liu contributing as a co-portfolio manager and sector specialist. That experienced management bench is relevant for investors assessing process stability and research quality. Recent filings and fund disclosures available in 2026 indicate continued use of BlackRock’s discount management program and ongoing shareholder reporting, both important for a listed closed-end structure. For French-speaking investors, the central takeaway is that BME is a NYSE-listed United States healthcare income vehicle with a quality-biased active strategy, but one that can trade at a discount or premium to NAV and therefore requires valuation discipline.